1799 – Transcatheter tricuspid valve replacement in patients with severe, symptomatic tricuspid regurgitation despite optimal medical therapy

New Medicare Benefits Schedule item.

The EVOQUE Tricuspid Valve Replacement System is a minimally invasive transcatheter device designed to replace the tricuspid valve without open-heart surgery. It is delivered through a transfemoral approach using a specially designed delivery system. By replacing the dysfunctional tricuspid valve with a bioprosthetic valve, EVOQUE prevents backflow, reducing tricuspid regurgitation (TR) severity and improving blood flow dynamics in the heart. 

Type: Therapeutic

Tricuspid regurgitation (TR) is a heart valve condition where the tricuspid valve doesn't close properly, allowing blood to flow backward from the right ventricle into the right atrium. TR is classified by leaflet pathology as primary (due to abnormal tricuspid valve leaflets) or secondary (due to presence of left-sided heart disease). The severity of TR is categorised by the American Society of Echocardiography’s (ASE) three-tiered grading scale to describe the different stages of TR including mild, moderate, and severe.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: 14 March 2025
• Pre-MSAC consultation deadline: -

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 16 to 17 April 2025
• ESC meeting: -
• MSAC meeting: -

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.